MALVERN, Pa. & MONTRÉAL--(BUSINESS WIRE)--Gemin X Pharmaceuticals announced today that preclinical data from the company’s targeted cancer therapy, obatoclax (GX15-070), an innovative pan-Bcl2 inhibitor, will be presented in three oral sessions and two poster sessions during the 50th Annual American Society of Hematology (ASH) Meeting and Exposition in San Francisco December 6-9, 2008.
